Compare · CNC vs OPGN
CNC vs OPGN
Side-by-side comparison of Centene Corporation (CNC) and OpGen Inc. (OPGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and OPGN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $45.09B, about 1175.0x OPGN ($38.4M).
- Over the past year, CNC is down 29.8% and OPGN is up 0.0% - OPGN leads by 29.8 points.
- CNC has hit the wire 8 times in the past 4 weeks while OPGN has been quiet.
- CNC has more recent analyst coverage (25 ratings vs 0 for OPGN).
- Company
- Centene Corporation
- OpGen Inc.
- Price
- $41.83+1.76%
- $1.96-14.04%
- Market cap
- $45.09B
- $38.4M
- 1M return
- +27.87%
- +0.00%
- 1Y return
- -29.76%
- +0.00%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
OpGen Inc.
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is based in Rockville, Maryland.
Latest CNC
- Centene Foundation Reports $34.9 Million Invested in Community Health, Education and Social Services in 2025
- Superior HealthPlan Employees Contributed More Than 3,000 Volunteer Hours Across Texas Communities in 2025
- Los Angeles Residents to Gain Faster Access to New Affordable Housing through Health Net's $10 Million Investment in "Guarantee Fund"
- Home State Health and Centene Foundation Launch Medical Respite Program in St. Louis
- SEC Form 4 filed by Mcnally Tanya M
- CENTENE CORPORATION TO HOST 2026 FIRST QUARTER FINANCIAL RESULTS EARNINGS CALL
- Sunshine Health Delivers Career Pathways for Floridians and Advances Healthcare Workforce
- Centene Announces New Executive Leadership Structure
- St. Vincent Behavioral Health Campus Expands Housing & Health Care for LA with $6M Health Net Investment
- Carolina Complete Health and WellCare of North Carolina Combine to Form Provider-Led Managed Care Organization
Latest OPGN
- SEC Form NT 10-K filed by OpGen Inc.
- OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
- OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form DEF 14A filed by OpGen Inc.
- SEC Form PRE 14A filed by OpGen Inc.
- OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- New insider Bonte Christian-Laurent claimed ownership of 28,571 shares (SEC Form 3)
- OpGen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by OpGen Inc.